InvestorsObserver
×
News Home

Where Will Dermata Therapeutics Inc (DRMA) Stock Go Next After It Has Risen 73.08% in a Week?

Thursday, June 30, 2022 11:06 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Dermata Therapeutics Inc (DRMA) Stock Go Next After It Has Risen 73.08% in a Week?

Overall market sentiment has been high on Dermata Therapeutics Inc (DRMA) stock lately. DRMA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Dermata Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on DRMA!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With DRMA Stock Today?

Dermata Therapeutics Inc (DRMA) stock has risen 66.36% while the S&P 500 is down -1.24% as of 11:06 AM on Thursday, Jun 30. DRMA is up $0.36 from the previous closing price of $0.54 on volume of 12,244,675 shares. Over the past year the S&P 500 is lower by -15.59% while DRMA is down -82.66%. DRMA lost -$1.31 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Dermata Therapeutics Inc click here.

More About Dermata Therapeutics Inc

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Click Here to get the full Stock Report for Dermata Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App